Secondary Data Analysis of Patients at Risk for CKD to Inspect CKD Prevalence, Diagnosis Rates, Diagnostic Behaviour, Treatment Patterns and Patient Characteristics (InspeCKD)
InspeCKD - Secondary Data Analysis of Patients at Risk for Chronic Kidney Disease (CKD) in German Primary Care Offices to Inspect CKD Prevalence, Diagnosis Rates, Diagnostic Behaviour, Treatment Patterns and Patient Characteristics
Study Overview
Status
Status
Conditions
Conditions
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: AstraZeneca Clinical Study Information Center
- Phone Number: 1-877-240-9479
- Email: information.center@astrazeneca.com
Study Locations
-
-
-
Koblenz, Germany
- Research Site
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Age ≥ 18 years at start of the patient´s observation period
Having at least one of the following diseases (based on the documented ICD-10 code):
- Type 1 diabetes
- Type 2 diabetes
- Hypertension
Cardiovascular disease, including:
- Coronary and/or other atherosclerosis
- Myocardial infarction
- Heart failure
- Peripheral arterial disease
- Arrythmia
- Stroke
- Having at least one year (52 weeks) of observation period
Exclusion Criteria: NA
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percentage of patients with diagnosed CKD
Time Frame: Dating back a maximum of 24 months from the date of first data transfer
|
To assess the prevalence of diagnosed and undiagnosed CKD among all eligible patients at high risk for the development and progression of CKD
|
Dating back a maximum of 24 months from the date of first data transfer
|
|
Percentage of patients with undiagnosed CKD
Time Frame: Dating back a maximum of 24 months from the date of first data transfer
|
To assess the prevalence of diagnosed and undiagnosed CKD among all eligible patients at high risk for the development and progression of CKD
|
Dating back a maximum of 24 months from the date of first data transfer
|
|
Percentage of patients with undiagnosed or diagnosed CKD
Time Frame: Dating back a maximum of 24 months from the date of first data transfer
|
To assess the prevalence of diagnosed and undiagnosed CKD among all eligible patients at high risk for the development and progression of CKD
|
Dating back a maximum of 24 months from the date of first data transfer
|
|
Percentage of patients that fulfil CKD definition according to KDIGO (Kidney Disease: Improving Global Outcomes)
Time Frame: Dating back a maximum of 24 months from the date of first data transfer
|
To assess the prevalence of diagnosed and undiagnosed CKD among all eligible patients at high risk for the development and progression of CKD
|
Dating back a maximum of 24 months from the date of first data transfer
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Average number of serum creatinine measurements per patient per year (52 weeks) in the study period
Time Frame: Dating back a maximum of 24 months from the date of first data transfer
|
To evaluate the use of CKD-related laboratory diagnostics in all eligible patients
|
Dating back a maximum of 24 months from the date of first data transfer
|
|
Average number of UACR measurements per patient per year (52 weeks) during the study period
Time Frame: Dating back a maximum of 24 months from the date of first data transfer
|
To evaluate the use of CKD-related laboratory diagnostics in all eligible patients
|
Dating back a maximum of 24 months from the date of first data transfer
|
|
Percentage of patients with no, one, or at least two serum creatinine measurements among all eligible patients during the study period
Time Frame: Dating back a maximum of 24 months from the date of first data transfer
|
To evaluate the use of CKD-related laboratory diagnostics in all eligible patients
|
Dating back a maximum of 24 months from the date of first data transfer
|
|
Percentage of patients with no, one, or at least two UACR measurements among all eligible patients during the study period
Time Frame: Dating back a maximum of 24 months from the date of first data transfer
|
To evaluate the use of CKD-related laboratory diagnostics in all eligible patients
|
Dating back a maximum of 24 months from the date of first data transfer
|
|
Percentage of patients who did not have serum creatinine and UACR determined at least once
Time Frame: Dating back a maximum of 24 months from the date of first data transfer
|
To evaluate the use of CKD-related laboratory diagnostics in all eligible patients
|
Dating back a maximum of 24 months from the date of first data transfer
|
|
Percentage of patients in whom both serum creatinine and UACR were determined at least once
Time Frame: Dating back a maximum of 24 months from the date of first data transfer
|
To evaluate the use of CKD-related laboratory diagnostics in all eligible patients
|
Dating back a maximum of 24 months from the date of first data transfer
|
|
Percentage of patients in whom both serum creatinine and UACR were determined at least twice
Time Frame: Dating back a maximum of 24 months from the date of first data transfer
|
To evaluate the use of CKD-related laboratory diagnostics in all eligible patients
|
Dating back a maximum of 24 months from the date of first data transfer
|
|
Percentage of patients with at least two serum creatinine measurements with an interval of at least three months among all eligible patients in the study period
Time Frame: Dating back a maximum of 24 months from the date of first data transfer
|
To evaluate the use of CKD-related laboratory diagnostics in all eligible patients
|
Dating back a maximum of 24 months from the date of first data transfer
|
|
Percentage of patients with at least two UACR measurements with an interval of at least three months among all eligible patients in the study period
Time Frame: Dating back a maximum of 24 months from the date of first data transfer
|
To evaluate the use of CKD-related laboratory diagnostics in all eligible patients
|
Dating back a maximum of 24 months from the date of first data transfer
|
|
Percentage of patients with at least two UACR and serum creatinine measurements with an interval of at least three months among all eligible patients in the study period
Time Frame: Dating back a maximum of 24 months from the date of first data transfer
|
To evaluate the use of CKD-related laboratory diagnostics in all eligible patients
|
Dating back a maximum of 24 months from the date of first data transfer
|
|
Age at index date
Time Frame: Dating back a maximum of 24 months from the date of first data transfer
|
To describe baseline characteristics among patients with diagnosed and undiagnosed CKD at index date
|
Dating back a maximum of 24 months from the date of first data transfer
|
|
Sex at index date
Time Frame: Dating back a maximum of 24 months from the date of first data transfer
|
To describe baseline characteristics among patients with diagnosed and undiagnosed CKD at index date
|
Dating back a maximum of 24 months from the date of first data transfer
|
|
BMI at index date
Time Frame: Dating back a maximum of 24 months from the date of first data transfer
|
To describe baseline characteristics among patients with diagnosed and undiagnosed CKD at index date
|
Dating back a maximum of 24 months from the date of first data transfer
|
|
Concurrent medication at index date
Time Frame: Dating back a maximum of 24 months from the date of first data transfer
|
To describe baseline characteristics among patients with diagnosed and undiagnosed CKD at index date
|
Dating back a maximum of 24 months from the date of first data transfer
|
|
Comorbidities at index date
Time Frame: Dating back a maximum of 24 months from the date of first data transfer
|
To describe baseline characteristics among patients with diagnosed and undiagnosed CKD at index date
|
Dating back a maximum of 24 months from the date of first data transfer
|
|
eGFR values at index date
Time Frame: Dating back a maximum of 24 months from the date of first data transfer
|
To describe baseline characteristics among patients with diagnosed and undiagnosed CKD at index date
|
Dating back a maximum of 24 months from the date of first data transfer
|
|
UACR values at index date
Time Frame: Dating back a maximum of 24 months from the date of first data transfer
|
To describe baseline characteristics among patients with diagnosed and undiagnosed CKD at index date
|
Dating back a maximum of 24 months from the date of first data transfer
|
|
Percentage of patients among diagnosed or undiagnosed CKD patients that are treated with either/or renin-angiotensin-system-inhibitors (ACEi, ARB), SGLT2i, statin or selective mineralocorticoid receptor antagonist at index date
Time Frame: Dating back a maximum of 24 months from the date of first data transfer
|
To evaluate the use of medication to treat CKD among patients with diagnosed and undiagnosed CKD
|
Dating back a maximum of 24 months from the date of first data transfer
|
|
Percentage of patients among diagnosed or undiagnosed CKD patients that are newly initiated with either/or renin-angiotensin-system-inhibitors (ACEi, ARB), SGLT2i, statin, selective mineralocorticoid receptor antagonist within 6 months after index date
Time Frame: Dating back a maximum of 24 months from the date of first data transfer
|
To evaluate the use of medication to treat CKD among patients with diagnosed and undiagnosed CKD
|
Dating back a maximum of 24 months from the date of first data transfer
|
|
Percentage of patients with impaired kidney function
Time Frame: Dating back a maximum of 24 months from the date of first data transfer
|
To assess the prevalence of impaired kidney function in all eligible patients
|
Dating back a maximum of 24 months from the date of first data transfer
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percentage of patients among patients with diagnosed / undiagnosed CKD with at least one measurement of serum creatinine and UACR once per year (as recommended by KDIGO or ADA) in the study period
Time Frame: Dating back a maximum of 24 months from the date of first data transfer
|
To assess guideline adherence and achievement of target values for the use of CKD-related laboratory diagnostics, the use of recommended CKD therapies and therapeutic target values in patients with diagnosed and undiagnosed CKD
|
Dating back a maximum of 24 months from the date of first data transfer
|
|
Percentage of patients among patients with diagnosed / undiagnosed CKD that reached target values for blood pressure (as recommended by KDIGO) within 6 month (26 weeks) after index date
Time Frame: Dating back a maximum of 24 months from the date of first data transfer
|
To assess guideline adherence and achievement of target values for the use of CKD-related laboratory diagnostics, the use of recommended CKD therapies and therapeutic target values in patients with diagnosed and undiagnosed CKD
|
Dating back a maximum of 24 months from the date of first data transfer
|
|
Percentage of patients among patients with diagnosed / undiagnosed CKD with guideline adherent medication as recommended by KDIGO, ADA or DEGAM within 6 month (26 weeks) after index date
Time Frame: Dating back a maximum of 24 months from the date of first data transfer
|
To assess guideline adherence and achievement of target values for the use of CKD-related laboratory diagnostics, the use of recommended CKD therapies and therapeutic target values in patients with diagnosed and undiagnosed CKD
|
Dating back a maximum of 24 months from the date of first data transfer
|
|
Time (in weeks) from first eGFR value below 60 ml/min/1.73 m2 until the second measurement of eGFR in patients who have a reported second measurement
Time Frame: Dating back a maximum of 24 months from the date of first data transfer
|
To assess time from first eGFR value below 60 ml/min/1.73
m2 until a second estimation is performed in all eligible patients
|
Dating back a maximum of 24 months from the date of first data transfer
|
|
Time (in weeks) from first UACR value above 30 mg/g until the second measurement of UACR in patients who have a reported second measurement
Time Frame: Dating back a maximum of 24 months from the date of first data transfer
|
To assess time from first UACR value above 30 mg/g until a second measurement of UACR is performed in all eligible patients
|
Dating back a maximum of 24 months from the date of first data transfer
|
|
Time (in weeks) from first UACR value above 300 mg/g until the second measurement of UACR in patients who have a reported second measurement
Time Frame: Dating back a maximum of 24 months from the date of first data transfer
|
To assess time from first UACR value above 300 mg/g until a second measurement of UACR is performed in all eligible patients
|
Dating back a maximum of 24 months from the date of first data transfer
|
|
Time (in weeks) from first fulfilment of CKD definition to coding of ICD-10 code for CKD
Time Frame: Dating back a maximum of 24 months from the date of first data transfer
|
To assess time from first fulfilment of CKD definition to diagnosis (by ICD-10 code) in all eligible patients
|
Dating back a maximum of 24 months from the date of first data transfer
|
|
Time (in weeks) from CKD diagnosis among priorly undiagnosed patients to first prescription of RASi, SGLT2i, statin or MRA (Finerenone)
Time Frame: Dating back a maximum of 24 months from the date of first data transfer
|
To assess time from CKD diagnosis in priorly undiagnosed patients to initiation of RASi, SGLT2i, statin or Finerenone therapy
|
Dating back a maximum of 24 months from the date of first data transfer
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- D1843R00351
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.